AMAT vs PFE: Which Is the Better Buy?
Side-by-side comparison of Applied Materials, Inc. and Pfizer Inc. — fair value, conviction, valuation metrics, and QuantHub research signals.
Updated 2026-07-06.
Applied Materials, Inc. · Technology
$603.04
-45.0% upside to fair value
Grade C
High Quality
VS
Pfizer Inc. · Healthcare
$25.22
+2.8% upside to fair value
Grade B
QuantHub Verdict
PFE has more upside to fair value
(+2.8%).
PFE trades at a lower forward P/E
(19.2x).
These are model outputs — not personalized investment advice.
See all research →
Valuation & Fundamentals
| Metric |
AMAT |
PFE |
| Current Price |
$603.04 |
$25.22 |
| Fair Value Estimate |
$331.67 |
$25.92 |
| Upside to Fair Value |
-45.0%
|
+2.8%
|
| Market Cap |
$478.8B |
$143.7B |
| Forward P/E |
56.4x
|
19.2x
|
| EV / EBITDA |
43.0x
|
12.3x
|
| Price / Sales |
16.5x
|
2.3x
|
| Price / FCF |
80.3x
|
15.2x
|
| Revenue Growth YoY |
+11.4%
|
+5.4%
|
| Gross Margin |
49.0%
|
69.3%
|
| Operating Margin |
29.5%
|
23.4%
|
| Return on Equity |
39.8%
|
8.4%
|
| Dividend Yield |
0% |
0% |
| FCF Yield |
1.25%
|
6.6%
|
| Analyst Consensus |
Strong Buy
|
Hold
|
Investment Thesis
Applied Materials, Inc. is a leading semiconductor equipment company with a strong competitive moat in multiple wafer fab equipment segments, driven by its scale, infrastructure, and technology leadership in AI-critical process steps. The company benefits from a seasoned management team led by CEO Gary Dickerson, who has over 12 years at the helm and a track record of strong revenue and profitabi…
Pfizer Inc. is a leading global biopharmaceutical company with a diversified portfolio dominated by its Biopharma prescription segment, which accounts for over 90% of revenue. The company benefits from a substantial scale, a broad product portfolio including top-selling drugs like Eliquis, Prevnar, and Paxlovid, and a strong manufacturing footprint. However, Pfizer faces challenges from declining…
Accumulation Zones
| Metric |
AMAT |
PFE |
| Zone Low |
$248.75 |
$19.44 |
| Zone High |
$281.92 |
$22.03 |
| In Buy Zone? |
No
|
No
|